Frank P. Luyten
Director/Board Member at PharmaCell BV
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Casper F. Bruens | M | 65 |
PharmaCell BV
PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | - |
Koenraad Debackere | M | 63 |
Université Catholique de Louvain
| 29 years |
Michel J. Tilmant | M | 71 |
Université Catholique de Louvain
| - |
Daan van den Noort | M | - |
PharmaCell BV
PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | - |
Minne Casteels | M | - |
Université Catholique de Louvain
| - |
Mark Waer | M | - |
Université Catholique de Louvain
| - |
Vic Goedseels | M | 83 |
Université Catholique de Louvain
| 45 years |
Johan van den Driessche | M | 71 |
Prometheus
Prometheus Packaged SoftwareTechnology Services Prometheus is an independent network of four southern-European think tanks that specialize in economic, business, and geopolitical research. The private company is based in Antwerp, Belgium, and have subsidiaries in Belgium. Prometheus recently published a report on the music production and reproduction ecosystem. The Belgian company was founded in 2006 by Clyde Davis. | - |
Joseph Martin | M | - |
Université Catholique de Louvain
| - |
Françoise de Viron | M | 69 |
Université Catholique de Louvain
| - |
Pieter ter Kuile | M | - |
PharmaCell BV
PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | - |
Pieter de Geus | M | - |
Neuroplast BV
Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | 3 years |
Johannes de Munter | M | - |
Neuroplast BV
Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | 8 years |
Hans Preusting | M | 62 |
PharmaCell BV
PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | - |
Marianne van der Steen | M | - |
Neuroplast BV
Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | - |
Wim Brouwer | M | - |
Neuroplast BV
Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | - |
Lucien Wilms | M | - |
Prometheus
Prometheus Packaged SoftwareTechnology Services Prometheus is an independent network of four southern-European think tanks that specialize in economic, business, and geopolitical research. The private company is based in Antwerp, Belgium, and have subsidiaries in Belgium. Prometheus recently published a report on the music production and reproduction ecosystem. The Belgian company was founded in 2006 by Clyde Davis. | 18 years |
Marc van Gysel | M | - |
Prometheus
Prometheus Packaged SoftwareTechnology Services Prometheus is an independent network of four southern-European think tanks that specialize in economic, business, and geopolitical research. The private company is based in Antwerp, Belgium, and have subsidiaries in Belgium. Prometheus recently published a report on the music production and reproduction ecosystem. The Belgian company was founded in 2006 by Clyde Davis. | 18 years |
Wim Vermeulen | M | - |
Prometheus
Prometheus Packaged SoftwareTechnology Services Prometheus is an independent network of four southern-European think tanks that specialize in economic, business, and geopolitical research. The private company is based in Antwerp, Belgium, and have subsidiaries in Belgium. Prometheus recently published a report on the music production and reproduction ecosystem. The Belgian company was founded in 2006 by Clyde Davis. | 18 years |
Hans Henskens | M | - |
PharmaCell BV
PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | - |
Robert Cobbaut | M | - |
Université Catholique de Louvain
| - |
Pieter Vanthemsche | M | 68 |
Université Catholique de Louvain
| - |
Pierre Scalliet | M | 72 |
Université Catholique de Louvain
| - |
François Dupret | M | - |
Université Catholique de Louvain
| - |
Pierre de Muelenaere | M | 65 |
Université Catholique de Louvain
| - |
Baron Jean Stéphenne | M | 73 |
Université Catholique de Louvain
| - |
Maurice Luc Vandenbroucke | M | 74 |
Université Catholique de Louvain
| - |
Ivo Roelants | M | - |
Université Catholique de Louvain
| - |
Marcel Kloosterman | M | - |
Neuroplast BV
Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | - |
Jan Delcour | M | - |
Université Catholique de Louvain
| 33 years |
Roger Marcel Henri Legras | M | - |
Université Catholique de Louvain
| - |
Serge Pampfer | M | - |
Université Catholique de Louvain
| - |
Jean-Pierre Hansen | M | 76 |
Université Catholique de Louvain
| - |
Etienne Marc Sokal | M | - |
Université Catholique de Louvain
| - |
Yves-Jacques Schneider | M | - |
Université Catholique de Louvain
| - |
Luc Willame | M | 81 |
Université Catholique de Louvain
| - |
Erik Duval | M | - |
Université Catholique de Louvain
| - |
Eric Stroobants | M | 81 |
Université Catholique de Louvain
| - |
Brigitte Chanoine | M | 58 |
Université Catholique de Louvain
| - |
Michèle Detaille | F | 67 |
Université Catholique de Louvain
| 19 years |
Koen Huygens | M | - | 23 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gil Beyen | M | 62 | 13 years | |
Willy W. Duron | M | 79 | - | |
Sven Arne Andréasson | M | 72 | 2 years | |
Dirk Reyn | M | 62 | 5 years | |
Eduardo Bravo Fernández de Araoz | M | 58 | 13 years | |
Claudia D'Augusta | M | 54 | 7 years | |
Frank Hazevoets | M | 57 | 6 years | |
An Moonen | F | - | 8 years | |
Joël Jean-Mairet | M | 52 | 2 years | |
Raf Moons | M | - | - | |
Koenraad Blot | M | 62 | - | |
Heico Breek | M | - | 4 years | |
Luc van de Steen | M | 62 | 8 years | |
Luc Dochez | M | 49 | 5 years | |
Marleen Johanna Limbourg | M | - | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 46 | 82.14% |
Netherlands | 10 | 17.86% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Frank P. Luyten
- Personal Network